At a webinar hosted by the federal Substances and Mental Health Services Administration (SAMHSA) last week, a leading cannabis researcher threw cold water on the notion that legalizing marijuana leads to increases in youth use of the drug. He also touched on problems with roadside assessments of cannabis impairment, the risk of testing positive for THC after using CBD products and the need for more nuanced regulation around cannabinoids themselves.
The public talk, from Ryan Vandry, an experimental psychologist and professor at Johns Hopkins University’s Behavioral Pharmacology Research Unit, was aimed at providing continuing education on marijuana for healthcare professionals. Titled “Behavioral Pharmacology of Cannabis – Trends in Use, Novel Products, and Impact,” it focused primarily on how variables like dosage, product formulation, mode of administration and chemical components such as terpenes can influence the drug’s effects.
Vandry began by noting that marijuana is the most commonly used illicit drug in the United States. While self-reported consumption by adults has risen as more states have legalized in recent years, he noted, use by youth has generally remained flat or fallen.
“Use among youth is one of the biggest areas of concern related to the legalization and increased accessibility of cannabis,” he said, “but surprisingly, that cohort has actually maintained relatively stable [for] both past-year and daily use.”
Pointing to data from California going back to 1996, when the state ended prohibition for medical patients, Vandry said there has “really been no change in the rates of cannabis use among eighth, 10th or 12th graders. And in fact, in very recent years, we’ve seen a decrease in rates of consumption.”
You must be logged in to post a comment.